Research Analysts’ Weekly Ratings Changes for Kyntra Bio (KYNB)

Several brokerages have updated their recommendations and price targets on shares of Kyntra Bio (NASDAQ: KYNB) in the last few weeks:

• 10/26/2026 – Kyntra Bio was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 10/13/2026 – Kyntra Bio is now covered by Maxim Group. They set a “buy” rating and a $35.00 price target on the stock.
• 10/12/2026 – Kyntra Bio was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/9/2026 – Kyntra Bio was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/17/2026 – Kyntra Bio is now covered by Lake Street Capital. They set a “buy” rating and a $41.00 price target on the stock.
• 9/17/2026 – Kyntra Bio is now covered by Lake Street Capital. They set a “buy” rating and a $41.00 price target on the stock.
• 9/1/2026 – Kyntra Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $43.00 price target on the stock.

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.